By Product Type
By Research Area
|Date||Thursday 29th April 2021|
|Time||3pm BST / 9am CDT / 10am EDT|
|Venue||Zoom - Register here|
Proteintech is excited to announce our first ever Cancer-Immunotherapy meeting for Early-Career Researchers. At a time when physical meetings are not possible, we want to provide a platform for young scientists to present their work to an international audience and create opportunities for networking and open communication.
Full meeting program - coming soon
Abstract* submission is open to all PhD Students and Postdocs researching Cancer Immunotherapies. Four ECR students will be chosen for a short talk from our panel of independent judges and win a prize of $250.
Abstract deadline is the 25th of March 2021.
*Abstracts will be judged by an independent panel of post-docs and early career fellows.
Dr John Maher
Clinical Immunologist, Kings College London, UK
"CAR T-Cell Immunotherapy of Solid Tumors: Learning from the Clinic and Lab in Parallel"
Dr John Maher is a clinical immunologist who leads the "CAR Mechanics" research group within King's College London. He played a key role in the early development of second generation (CD28) CAR technology while a visiting fellow at Memorial Sloan Kettering Cancer Center, an approach that has achieved clinical impact in haematological malignancies. His research group is focused on the development of adoptive immunotherapy using CAR engineered and gamma delta T-cells, with a primary emphasis on solid tumour types. He is also the scientific founder and chief scientific officer of a spin-out company named Leucid Bio. In addition, he is a consultant immunologist within King's Health Partners and Eastbourne Hospital.
|Want to just watch? This event is free to attend, register here|
Places are allocated on a 'first come, first served' basis. Register early to avoid disappointment! All registered attendees will receive an email confirmation from Zoom with your unique link to join the event.
For more information please email email@example.com.